CommercialCoverageMedium impact
08.00.74aa, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
The intravitreal injection policy for VEGF antagonists, VEGF biosimilars, and combination VEGF/Ang-2 inhibitors has been updated for commercial plans. This affects coverage and billing requirements for eye injections commonly used to treat retinal conditions like macular degeneration and diabetic retinopathy.
Action Required
By October 1, 2025: Billing team should review the full policy at the provided URL to understand specific coverage changes for intravitreal VEGF injections. Update billing procedures and prior authorization requirements as specified in the complete policy document. Coordinate with ophthalmology providers to ensure compliance with new guidelines.